Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado.

Edgewise Therapeutics Inc.

Evercore ISI analyst Cory Kasimov maintained a Buy rating on Edgewise Therapeutics yesterday and set a price target of $30.00. The company’s shares...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	EWTX	$23.62	+0.81%	2.34M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	EWTX	$23.62	+0.8%	2.34M
3
4
5
6

EWTX

EWTX

No Data Available

Get Edgewise Therapeutics Inc. Data in Excel

Get Edgewise Therapeutics Inc. Data in Excel